| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yang-Ping Shentu, Yuda Huo, Xiao-Long Feng, James Gilbert, Qing Zhang, Zhen-Yu Liuyang, Xiu-Lian Wang, Guan Wang, Huan Zhou, Xiao-Chuan Wang, Jian-Zhi Wang, You-Ming Lu, Jukka Westermarck, Heng-Ye Man, Rong Li. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease. Cell reports. vol 24. issue 3. 2019-12-03. PMID:30021167. |
protein phosphatase 2a (pp2a) inhibition causes hyperphosphorylation of tau and app in alzheimer's disease (ad). |
2019-12-03 |
2023-08-13 |
mouse |
| Valeria Lifke, Gwendlyn Kollmorgen, Ekaterina Manuilova, Tobias Oelschlaegel, Lars Hillringhaus, Monika Widmann, Christine A F von Arnim, Markus Otto, Robert H Christenson, Jennifer L Powers, Leslie M Shaw, Oskar Hansson, James D Doecke, Qiao-Xin Li, Charlotte Teunissen, Hayrettin Tumani, Kaj Blenno. Elecsys Clinical biochemistry. vol 72. 2019-12-03. PMID:31129184. |
elecsys total tau (ttau) and phosphorylated 181p tau (ptau) are supportive diagnostic cerebrospinal fluid (csf) biomarkers for alzheimer's disease. |
2019-12-03 |
2023-08-13 |
Not clear |
| Tanguy Fenouil, Anthony Fourier, Isabelle Quadrio, Nathalie Streichenberger, Sergio Bernardini, Tomáš Zima, Armand Perret-Liaudet, David Meyrone. The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers? Clinical biochemistry. vol 72. 2019-12-03. PMID:31194969. |
this brings new challenges to laboratory medicine in the field of cerebrospinal fluid (csf) markers of alzheimer's disease: how to further validate total tau, phospho-tau, aß40 and aß42 and new marker level cut-offs while autopsy rates are declining? |
2019-12-03 |
2023-08-13 |
Not clear |
| Giulia Sancesario, Sergio Bernardin. AD biomarker discovery in CSF and in alternative matrices. Clinical biochemistry. vol 72. 2019-12-03. PMID:31437430. |
core alzheimer's disease (ad) biomarkers are the cerebrospinal fluid (csf) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. |
2019-12-03 |
2023-08-13 |
Not clear |
| Neng-Wei Hu, Grant T Corbett, Steven Moore, Igor Klyubin, Tiernan T O'Malley, Dominic M Walsh, Frederick J Livesey, Michael J Rowa. Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity. Cell reports. vol 23. issue 7. 2019-12-02. PMID:29768194. |
extracellular forms of aβ and tau from ipsc models of alzheimer's disease disrupt synaptic plasticity. |
2019-12-02 |
2023-08-13 |
human |
| Taxiarchis Katsinelos, Marcel Zeitler, Eleni Dimou, Andromachi Karakatsani, Hans-Michael Müller, Eliana Nachman, Julia P Steringer, Carmen Ruiz de Almodovar, Walter Nickel, Thomas R Jah. Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. Cell reports. vol 23. issue 7. 2019-12-02. PMID:29768203. |
the progressive deposition of misfolded hyperphosphorylated tau is a pathological hallmark of tauopathies, including alzheimer's disease. |
2019-12-02 |
2023-08-13 |
Not clear |
| Valentina De Riva, Elisabetta Galloni, Barbara Lealini, Giulia Zarantonello, Caterina Disco, Laura Di Dionisio, Lucia Meligrana, Michela Marcon, Francesco Perin. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias. Clinical laboratory. vol 65. issue 5. 2019-12-02. PMID:31115229. |
patients with alzheimer's disease (ad) present a typical biochemical profile of biomarkers: low concentration of β amyloid 1-42 (aβ1-42), high concentration of total tau (t-tau) and phosphorylated tau at threonine 181 (p-tau). |
2019-12-02 |
2023-08-13 |
human |
| Valentina De Riva, Elisabetta Galloni, Barbara Lealini, Giulia Zarantonello, Caterina Disco, Laura Di Dionisio, Lucia Meligrana, Michela Marcon, Francesco Perin. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias. Clinical laboratory. vol 65. issue 5. 2019-12-02. PMID:31115229. |
it has been hypothesized that subjects with dementia due to ad showed low levels of aβ1-42 combined with the highest levels of total tau and phosphorylated tau; moreover, it has been hypothesized that the ratio aβ1-42:p-tau further help in discriminating alzheimer's disease from other diagnoses. |
2019-12-02 |
2023-08-13 |
human |
| Dieter Willbold, Janine Kutzsch. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease? Molecules (Basel, Switzerland). vol 24. issue 12. 2019-12-02. PMID:31208037. |
while phase iii clinical trials for the treatment of alzheimer's disease (ad) keep failing regardless of the target, more and more data suggest that the toxic protein assemblies of amyloid-beta protein (aβ) and tubulin binding protein (tau) behave like prions. |
2019-12-02 |
2023-08-13 |
Not clear |
| Vivek Baghel, Madhavi Tripathi, Girish Parida, Ravikant Gupta, Saroj Yadav, Praveen Kumar, A B Dey, Nishikant Avinash Damle, Rajeev Kumar, Chandrasekhar Ba. In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition. Clinical nuclear medicine. vol 44. issue 11. 2019-11-29. PMID:31584490. |
in vivo assessment of tau deposition in alzheimer disease and assessing its relationship to regional brain glucose metabolism and cognition. |
2019-11-29 |
2023-08-13 |
Not clear |
| Vivek Baghel, Madhavi Tripathi, Girish Parida, Ravikant Gupta, Saroj Yadav, Praveen Kumar, A B Dey, Nishikant Avinash Damle, Rajeev Kumar, Chandrasekhar Ba. In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition. Clinical nuclear medicine. vol 44. issue 11. 2019-11-29. PMID:31584490. |
in this study, we investigated the relationship of cerebral tau deposition (f-tau-ad-ml 104 pet/ct) with glucose metabolism (f-fdg pet/ct) and cognitive function in patients with alzheimer disease (ad). |
2019-11-29 |
2023-08-13 |
Not clear |
| Thomas K Karikari, David A Nagel, Alastair Grainger, Charlotte Clarke-Bland, Eric J Hill, Kevin G Moffa. Preparation of stable tau oligomers for cellular and biochemical studies. Analytical biochemistry. vol 566. 2019-11-27. PMID:30315761. |
increasing evidence suggests that small oligomers are the principal neurotoxic species of tau in alzheimer's disease and other tauopathies. |
2019-11-27 |
2023-08-13 |
human |
| Jangampalli Adi Pradeepkiran, P Hemachandra Redd. Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer's Disease. Cells. vol 8. issue 3. 2019-11-27. PMID:30893872. |
structure based design and molecular docking studies for phosphorylated tau inhibitors in alzheimer's disease. |
2019-11-27 |
2023-08-13 |
Not clear |
| Jingfei Chen, Zhimin Long, Yanzhen Li, Min Luo, Shifang Luo, Guiqiong H. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model. International journal of molecular medicine. vol 44. issue 1. 2019-11-27. PMID:31115485. |
the abnormal activation of glycogen synthase kinase 3β (gsk3β) is one of the mechanisms involved in the pathogenesis of alzheimer's disease (ad), which results in amyloid β‑peptide (aβ) plaque overproduction, tau hyperphosphorylation and neuronal loss. |
2019-11-27 |
2023-08-13 |
mouse |
| Ruensern Tan, Aileen J Lam, Tracy Tan, Jisoo Han, Dan W Nowakowski, Michael Vershinin, Sergi Simó, Kassandra M Ori-McKenney, Richard J McKenne. Microtubules gate tau condensation to spatially regulate microtubule functions. Nature cell biology. vol 21. issue 9. 2019-11-26. PMID:31481790. |
tau aggregation into insoluble fibrils is a hallmark of alzheimer's disease and other types of dementia |
2019-11-26 |
2023-08-13 |
Not clear |
| Garrett S Gibbons, Virginia M Y Lee, John Q Trojanowsk. Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review. JAMA neurology. vol 76. issue 1. 2019-11-25. PMID:30193298. |
intracellular tau protein aggregates are a pathological hallmark of neurodegenerative tauopathies, including alzheimer disease (ad), progressive supranuclear palsy (psp), corticobasal degeneration (cbd), and pick disease. |
2019-11-25 |
2023-08-13 |
Not clear |
| Nancy Bartolotti, Ahmed Disouky, Arthur Kalinski, Anat Elmann, Orly Lazaro. Phytochemicals from Achillea fragrantissima are Modulators of AβPP Metabolism. Journal of Alzheimer's disease : JAD. vol 66. issue 4. 2019-11-25. PMID:30400087. |
here, we examined the effect of two af-derived phytochemicals on learning and memory, amyloid-β protein precursor (aβpp) metabolism, and tau phosphorylation in the familial alzheimer's disease-linked appswe/ps1Δe9 mouse model. |
2019-11-25 |
2023-08-13 |
mouse |
| Lilian Calderón-Garcidueñas, Partha S Mukherjee, Katharina Waniek, Max Holzer, Chih-Kai Chao, Charles Thompson, Rubén Ruiz-Ramos, Ana Calderón-Garcidueñas, Maricela Franco-Lira, Rafael Reynoso-Robles, Angélica Gónzalez-Maciel, Ingolf Lachman. Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution. Journal of Alzheimer's disease : JAD. vol 66. issue 4. 2019-11-25. PMID:30412505. |
non-phosphorylated tau in cerebrospinal fluid is a marker of alzheimer's disease continuum in young urbanites exposed to air pollution. |
2019-11-25 |
2023-08-13 |
Not clear |
| Rik Ossenkoppele, Ruben Smith, Tomas Ohlsson, Olof Strandberg, Niklas Mattsson, Philip S Insel, Sebastian Palmqvist, Oskar Hansso. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. vol 92. issue 6. 2019-11-25. PMID:30626656. |
associations between tau, aβ, and cortical thickness with cognition in alzheimer disease. |
2019-11-25 |
2023-08-13 |
Not clear |
| Rik Ossenkoppele, Ruben Smith, Tomas Ohlsson, Olof Strandberg, Niklas Mattsson, Philip S Insel, Sebastian Palmqvist, Oskar Hansso. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. vol 92. issue 6. 2019-11-25. PMID:30626656. |
to examine the cross-sectional associations between regional tau, β-amyloid (aβ), and cortical thickness and neuropsychological function across the preclinical and clinical spectrum of alzheimer disease (ad). |
2019-11-25 |
2023-08-13 |
Not clear |